CareRx Croissance future

Future contrôle des critères 0/6

CareRx devrait augmenter ses bénéfices et ses revenus de 29.1% et de 3.2% par an respectivement, tandis que le BPA devrait croître de croître de 120% par an.

Informations clés

29.1%

Taux de croissance des bénéfices

120.0%

Taux de croissance du BPA

Consumer Retailing croissance des bénéfices	5.5%
Taux de croissance des recettes	3.2%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Good
Dernière mise à jour	12 Nov 2024

Mises à jour récentes de la croissance future

Analyst Estimates: Here's What Brokers Think Of CareRx Corporation (TSE:CRRX) After Its Second-Quarter Report

Aug 11

Recent updates

CareRx (TSE:CRRX) Seems To Use Debt Quite Sensibly

Oct 03

Analyst Estimates: Here's What Brokers Think Of CareRx Corporation (TSE:CRRX) After Its Second-Quarter Report

Aug 11

Does CareRx (TSE:CRRX) Have A Healthy Balance Sheet?

Apr 22

Market Participants Recognise CareRx Corporation's (TSE:CRRX) Revenues Pushing Shares 28% Higher

Mar 17

Is CareRx Corporation's (TSE:CRRX) Shareholder Ownership Skewed Towards Insiders?

Mar 15

Trade Alert: The Chairman Emeritus Of CareRx Corporation (TSE:CRRX), Jack Shevel, Has Just Spent CA$850k Buying 9.4% More Shares

Feb 08

Prévisions de croissance des bénéfices et des revenus

TSX:CRRX - Estimations futures des analystes et données financières antérieures (CAD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	398	-3	N/A	N/A	4
12/31/2025	380	-4	17	23	8
12/31/2024	365	-3	27	33	8
9/30/2024	366	-6	31	38	N/A
6/30/2024	367	-7	27	34	N/A
3/31/2024	369	-4	23	32	N/A
12/31/2023	371	-5	19	27	N/A
9/30/2023	374	-6	25	33	N/A
6/30/2023	378	-7	30	38	N/A
3/31/2023	380	-34	16	29	N/A
12/31/2022	382	-34	9	22	N/A
9/30/2022	384	-34	-4	11	N/A
6/30/2022	358	-36	-5	10	N/A
3/31/2022	311	-20	-1	8	N/A
12/31/2021	263	-23	0	7	N/A
9/30/2021	212	-21	2	7	N/A
6/30/2021	187	-24	-6	-3	N/A
3/31/2021	177	-29	-2	0	N/A
12/31/2020	162	-18	-2	0	N/A
9/30/2020	148	-50	-3	-1	N/A
6/30/2020	134	-47	-2	0	N/A
3/31/2020	126	-34	-1	2	N/A
12/31/2019	125	-46	3	6	N/A
9/30/2019	122	-19	-1	3	N/A
6/30/2019	119	-20	-2	4	N/A
3/31/2019	117	-39	5	9	N/A
12/31/2018	119	-35	2	7	N/A
9/30/2018	85	-27	8	14	N/A
6/30/2018	97	-23	N/A	12	N/A
3/31/2018	110	-3	N/A	15	N/A
12/31/2017	122	-4	N/A	16	N/A
9/30/2017	168	-6	N/A	14	N/A
6/30/2017	170	-3	N/A	24	N/A
3/31/2017	170	-13	N/A	10	N/A
12/31/2016	167	-18	N/A	2	N/A
9/30/2016	166	-21	N/A	6	N/A
6/30/2016	166	-34	N/A	3	N/A
3/31/2016	164	-30	N/A	20	N/A
12/31/2015	161	-35	N/A	29	N/A
9/30/2015	27	-47	N/A	28	N/A
6/30/2015	60	-48	N/A	22	N/A
3/31/2015	97	-49	N/A	18	N/A
12/31/2014	135	-44	N/A	20	N/A
9/30/2014	301	-48	N/A	23	N/A
6/30/2014	295	-43	N/A	26	N/A
3/31/2014	289	-49	N/A	24	N/A
12/31/2013	281	-39	N/A	20	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: CRRX devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: CRRX devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: CRRX devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de CRRX ( 3.2% par an) devrait croître plus lentement que le marché de Canadian ( 7% par an).

Croissance élevée des revenus: Le chiffre d'affaires de CRRX ( 3.2% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de CRRX devrait être élevé dans 3 ans

CareRx Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

Price target decreased by 8.6% to CA$3.51

Analyst Estimates: Here's What Brokers Think Of CareRx Corporation (TSE:CRRX) After Its Second-Quarter Report

Consensus EPS estimates increase by 386%

Consensus EPS estimates fall by 29%

Forecast breakeven date pushed back to 2025

Price target decreased by 11% to CA$5.23

Recent updates

Price target decreased by 8.6% to CA$3.51

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

CareRx Corporation to Report Q3, 2024 Results on Nov 08, 2024

CareRx (TSE:CRRX) Seems To Use Debt Quite Sensibly

CareRx Corporation Appoints Suzanne Brand as Chief Financial Officer, Effective October 1, 2024

Analyst Estimates: Here's What Brokers Think Of CareRx Corporation (TSE:CRRX) After Its Second-Quarter Report

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

CareRx Corporation to Report Q2, 2024 Results on Aug 08, 2024

New minor risk - Insider selling

CareRx Corporation Announces Board Changes

Consensus EPS estimates increase by 386%

CareRx Corporation Announces CFO Transition

First quarter 2024 earnings: EPS exceeds analyst expectations

Does CareRx (TSE:CRRX) Have A Healthy Balance Sheet?

Market Participants Recognise CareRx Corporation's (TSE:CRRX) Revenues Pushing Shares 28% Higher

CareRx Corporation, Annual General Meeting, May 28, 2024

CareRx Corporation Reports Goodwill and Intangible Assets Impairment Charges for the Fourth Quarter Ended December 31, 2023

Full year 2023 earnings: EPS misses analyst expectations

CareRx Corporation to Report Q4, 2023 Results on Mar 07, 2024

New major risk - Revenue and earnings growth

Third quarter 2023 earnings: EPS exceeds analyst expectations

CareRx Corporation to Report Q3, 2023 Results on Nov 08, 2023

CareRx (TSE:CRRX) Takes On Some Risk With Its Use Of Debt

What You Can Learn From CareRx Corporation's (TSE:CRRX) P/S

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

CareRx Corporation to Report Q2, 2023 Results on Aug 10, 2023

Less than half of directors are independent

Carerx Corporation Announces Director Changes

First quarter 2023 earnings released: CA$0.039 loss per share (vs CA$0.059 loss in 1Q 2022)

Consensus EPS estimates fall by 29%

Forecast breakeven date pushed back to 2025

Price target decreased by 11% to CA$5.23

Full year 2022 earnings released: CA$0.72 loss per share (vs CA$0.65 loss in FY 2021)

CareRx Corporation has completed a Follow-on Equity Offering in the amount of CAD 8.0001 million.

CareRx Corporation announced that it expects to receive CAD 8.0001 million in funding

CareRx Announces Retirement of Dr. Jack Shevel as Director Effective December 31, 2022

No longer forecast to breakeven

Price target decreased to CA$6.09

Less than half of directors are independent

Price target decreased to CA$6.15

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

CareRx Corporation to Report Q3, 2022 Results on Nov 09, 2022

CareRx (TSE:CRRX) Has A Somewhat Strained Balance Sheet

Consensus forecasts updated

Price target decreased to CA$6.93

Carerx Corporation Reports Goodwill and Intangible Assets Impairment Changes for the Three Months Ended June 30, 2022

CareRx Corporation to Report Q2, 2022 Results on Aug 15, 2022

President recently sold CA$230k worth of stock

CareRx Corporation (TSX:CRRX) completed the acquisition of Hogan Pharmacy Partners Ltd.

Consensus EPS estimates fall by 597%

Price target decreased to CA$8.52

These 4 Measures Indicate That CareRx (TSE:CRRX) Is Using Debt Extensively

Forecast breakeven date pushed back to 2024

CareRx Corporation to Report Q1, 2022 Results on May 11, 2022

Consensus forecasts updated

Less than half of directors are independent

CareRx Corporation Announces Executive Changes

CareRx Corporation, Annual General Meeting, Jun 07, 2022

CareRx Corporation (TSX:CRRX) entered into a definitive asset purchase agreement to acquire Hogan Pharmacy Partners Ltd for $4.4 million.

CareRx Corporation (TSX:CRRX) entered into a definitive asset purchase agreement to acquire Hogan Pharmacy Partners Ltd for $4.4 million.

Consensus forecasts updated

No longer forecast to breakeven

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Carerx Corporation Expands the Scope and Product Offering of Its Medical Supplies Business Under A New Brand, Revicare

Here's Why CareRx (TSE:CRRX) Has A Meaningful Debt Burden

Third quarter 2021 earnings released: CA$0.11 loss per share (vs CA$0.28 loss in 3Q 2020)

CareRx Corporation (TSX:CRRX) completed the acquisition of Long-Term Care Pharmacy Division of Medical Pharmacies Group Limited for CAD 72.9 million.

Consensus EPS estimates fall to -CA$0.72